Nonalcoholic steatohepatitis (NASH) is a form of non-alcohol-related fatty liver disease. It is a chronic condition that can cause lasting damage to the liver. Non-alcohol-related fatty liver ...

MRE and MRI images from a cohort of NASH patients with F2-F3 fibrosis grades (n=152 observations), based on the NASH CRN score (F0-F4) were used to model the relationships between liver image ...

Non-alcoholic steatohepatitis (NASH) is a widespread disease affecting up to ~12% of the US population – characterized by lipid accumulation in hepatocytes, infiltration of immune cells and fibrosis ...

Findings showed that 26% and 30% of patients treated with resmetirom 80mg and 100mg, respectively, achieved NASH resolution with at least a 2-point reduction in NAS and no worsening of fibrosis ...

Sagimet's NASH drug-GLP-1 combo outperforms either alone for fibrosis By Helen Floersh Nov 29, 2023 8:06pm Sagimet Biosciences MASH GLP-1 Biotech ...

(HealthDay)—For patients with psoriasis receiving long-term methotrexate sodium therapy, a noninvasive test for nonalcoholic steatohepatitis (NASH) and hepatic fibrosis (NASH FibroSure) can be ...

Researchers also reported NASH resolution without worsening of fibrosis among 37% of patients in the 15 mg group (35 percentage points difference; 95% CI, 10-59), 23% in the 30 mg group (21 ...

VIENNA – Treatment with an investigational FGF21 analogue improved fibrosis in patients with nonalcoholic steatohepatitis (NASH), according to a phase IIb trial. In the ENLIVEN study, patients ...